Home   >  
Ion Channel/Membrane Transporter
  >  
CFTR

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

CFTR

Chemical Structure Cat. No. Product Name CAS No.
RTC13 Chemical Structure
 BCP48256 RTC13 313530-30-2
RTC13 is a premature termination codon (PTC) readthrough inducer that acts by restoring dystrophin expression and improving muscle function in the mdx mouse model for Duchenne muscular dystrophy.
Icenticaftor Chemical Structure
 BCP21194 Icenticaftor 1334546-77-8
Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively.
Crinecerfont hydrochloride Chemical Structure
 BCP43623 Crinecerfont hydrochloride 321839-75-2
Crinecerfont is a potent and orally bioactive corticotropin-releasing factor 1 receptor (CRF1) antagonist (pKi values of 8.73 and 9.08 for human cloned or native CRF1 receptors, respectively) with 1000-fold selectivity for CRF1 over CRF2α receptor and CRF binding protein.
Elexacaftor R enantiomer Chemical Structure
 BCP35907 Elexacaftor R enantiomer 2229860-99-3
Elexacaftor (VX-445,) is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR). Elexacaftor (VX-445) facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface.
Deutivacaftor Chemical Structure
 BCP19794 Deutivacaftor 1413431-07-8
Deutivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) channel activator potentially for the treatment of cystic fibrosis.
Elexacaftor Chemical Structure
 BCP29711 Elexacaftor 2216712-66-0
Elexacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR). CFTR corrector 1 (compound 1) facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface.
FDL169 Chemical Structure
 BCP30546 FDL169 1628416-28-3
FDL169 is an experimental therapy for cystic fibrosis (CF) that is being developed by Flatley Discovery Lab.
VX-659 Chemical Structure
 BCP29456 VX-659 2204245-48-5
VX-659 is a CFTR protein inhibitor.
ABBV-2222 Chemical Structure
 BCP25130 ABBV-2222 1918143-53-9
ABBV-2222, also known as GLPG2222, is a CFTR corrector being studied for the treatment of cystic fibrosis (CF).
Tezacaftor Chemical Structure
 BCP07173 Tezacaftor 1152311-62-0
Tezacaftor, also known asVX-661, is CFTR modulator. VX-661 is potentially useful for treatment of cystic fibrosis disease. Cystic fibrosis (CF) is a genetic disease caused by defects in the CF transmembrane regulator (CFTR) gene, which encodes an epithelial chloride channel. The most common mutation, Δ508CFTR, produces a protein that is misfolded and does not reach the cell membrane. VX-661 can correct trafficking of Δ508CFTR and partially restore chloride channel activity.
12下一页共 20 条记录 1 / 2 页 
0086-13720134139